万拉发新合并奎硫平治疗难治性抑郁症对照研究

Controlled study of venlafaxine combined with quetiapine in refractory depression

目的探讨万拉发新合并小剂量奎硫平治疗难治性抑郁症的疗效及安全性。方法将48例难治性抑郁症患者随机分为两组,每组各24例。研究组以万拉发新合并奎硫平进行治疗,对照组单用万拉发新治疗,疗程均为6w。治疗前及治疗第1、2、6w末采用汉密尔顿抑郁量表评定临床疗效,副反应量表评定不良反应。结果两组治疗第1w末汉密尔顿抑郁量表评分均有显著差异,减分率随治疗时间的延长逐渐提高。治疗1、2w末研究组较对照组见效快,差异有极显著性(P<0.01),6w末差异无显著性(P>0.05);6w末研究组有效率62.5%,对照组58.3%,两组差异无显著性(P>0.05)。不良反应均表现较轻,大多出现在治疗早期,经对症治疗逐渐缓解。结论万拉发新合并小剂量奎硫平治疗难治性抑郁症较单用万拉发新起效快,且不增加副作用。

Objective To explore the curative effects and safety of venlafaxine combined with small dose of quetiapine in the treatment of refractory depression. Methods 48 patients with refractory depression were randomly divided into research group(n = 24,venlafaxine combined with quetiapine)and control group(n = 24,single venlafaxine)for 6 weeks. Before treatment and at the ends of the 1st, 2nd and 6th week of treatment, clinical efficacy and side effects were assessed with Hamilton Depression Scale(HAMD) and Treatment Emergent Symptom Scale(TESS) , respectively. Results At the end of 1st week, the scores of HAMD in both the 2 groups had significant differences, score-reducing rates gradually increased along with treatment. In the 1st and 2nd week, the research group took effect faster than the control did, difference was more significant(P<0. 01) and no significant at the end of 6th week(PX). 05) ; at the end of 6th week, effective rates of the research and control groups were respectively 62. 5% and 58. 3% , which had no significant difference(P>0. 05) ; side effects of both the 2 groups were milder, most occurred in the initial stage of treatment and gradually remitted via expectant treatment. Conclusion Venlafaxine combined with small dose of quetiapine in refractory depression takes effects faster than single venlafaxine and doesn't increase side effects.